BMO Capital Downgrades Valeant Pharmaceuticals (VRX) to Market Perform; Cannot Defend the Specialty Pharmacy Structure

Valeant Pharma (VRX) Used Backdoor Approach to Gain Pharmacy Stake in California - ProPublica

October 22, 2015 5:48 PM EDT

Valeant Pharma (NYSE: VRX) is on watch following a new article from ProPublica which highlights documents that raise new questions about the company's pharmacy relationships in California.

From the... More

Citron Research to Discuss Valeant Pharma (VRX) at 12:30PM on Bloomberg

October 22, 2015 10:45 AM EDT

Citron Research said it will be on Bloomberg TV at 12:30PM ET to discuss Valeant Pharma (NYSE: VRX) which follows yesterday's scathing report and drastic sell-off.

Bloomberg's live feed can be found here:... More

Valeant Pharma (VRX) Resumes Free-Fall; Down 15%

October 22, 2015 9:44 AM EDT

Valeant Pharma (NYSE: VRX) is back testing the $100 level again. Shares down 15% currently.

Today's BMO Capital downgrade, highlighted earlier, is certainly not helping.

... More

Deutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating

October 22, 2015 9:37 AM EDT

Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.

Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More

Valeant's (VRX) Buy Rating Affirmed at BofA/Merrill Lynch

October 22, 2015 7:26 AM EDT

BofA/Merrill Lynch maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $290. Analyst Sumant S. Kulkarni said he continues to monitor concerns related to improper pricing and alleged irregularities in financial reporting, but he believes Valeant presents an "enhanced... More

Pershing Square's Ackman Down ~40% on Valeant Pharma (VRX) Bet

October 21, 2015 3:34 PM EDT

Pershing Square's Bill Ackman may have made a killing on Allergan (NYSE: AGN) following its sale to Actavis (NYSE: ACT), but the investor might see it all disappear with his bet on Valeant (NYSE:... More

Valeant Pharma (VRX) 'categorically' denies allegations in Citron report - CNBC

October 21, 2015 3:12 PM EDT

Valeant Pharma (NYSE: VRX) 'categorically' denies allegations in Citron report, according to CNBC.

... More

Ackman Affirms Buying Another 2M Valeant Pharma (VRX) Shares; Hasn't Sold Any - Bloomberg

October 21, 2015 2:58 PM EDT

Bill Ackman says he hasn't sold a share of Valeant Pharma (NYSE: VRX), according to Bloomberg, citing an email received earlier this afternoon. The investor also confirmed adding 2 million shares of VRX stock, as... More

UPDATE: Ackman Bought 2M More Shares of Valeant Pharma (VRX) - CNBC

October 21, 2015 2:38 PM EDT

(Updated - October 21, 2015 2:42 PM EDT)

Pershing Square's Bill Ackman bought 2 million more shares of Valeant Pharma (NYSE: VRX) today, according to CNBC.

Ackman's previously reported stake 19.47 million shares.... More

Valeant Pharma (VRX) Pares Decline on Trading Resumption

October 21, 2015 1:54 PM EDT

(Updated)

Valeant Pharma (NYSE: VRX) pared earlier declines after trading resumed following a T1 halt. The stock remains lower by 30% on the session.

... More

Valeant Pharma (VRX) resumes trading. Shares above $100 after trading below $90 pre-halt

October 21, 2015 1:54 PM EDT

Valeant Pharma (NYSE: VRX) resumes trading. Shares above $100 after trading below $90 pre-halt

... More

Valeant Pharma (VRX) Calls Citron Report 'Erroneous'

October 21, 2015 1:40 PM EDT

Valeant Pharma (NYSE: VRX) issued the following statement following earlier accusations of fraud by short seller Citron Research, which has sent shares down 39.5% today:

Philidor Rx Services is a pharmacy licensed in Pennsylvania and also provides back-end services, including call center,... More

Valeant Pharma (VRX) Halted, News Pending

October 21, 2015 1:31 PM EDT

Valeant Pharma (NYSE: VRX) Halted, News Pending

... More

Valeant Pharma (VRX) Taps Lows Below $90/Share

October 21, 2015 1:24 PM EDT

Valeant Pharma (NYSE: VRX) declined 38% to session lows at around 1:20 pm on Tuesday, briefly traded under $90 per share. The massive slide follows Citron Research's fraud report earlier. So far the company hasn't responded, which might be viewed as a negative by some investors.

... More

Hedge Funds on Edge as Valeant Pharma (VRX) Sinks

October 21, 2015 11:13 AM EDT

As Valeant (NYSE: VRX) shares plunge, the following are some notable holders of the company's stock, according to the latest regulatory filings:

T. Rowe Price - stake of 20,463,632 common shares, or about 6.1% of... More

Valeant Pharma (VRX) Halted on Circuit Breaker

October 21, 2015 10:24 AM EDT

Valeant Pharma (NYSE: VRX) Halted on Circuit Breaker

... More

Citron Research says it has a 'smoking gun' on Valeant Pharma (VRX)

October 21, 2015 10:10 AM EDT

(Updated - October 21, 2015 10:22 AM EDT)

Citron Research says it has a "smoking gun" on Valeant Pharma (NYSE: VRX) and lowered its price target to $50.

In a report entitled "Could this be the Pharmaceutical Enron?", Citron Research discusses the recently reported relationship with Philidor RX.

Citron also notes a court filing made by a company called R&O Pharmacy, filed with the California District Court in September, in which this small regional pharmacy... More

Valeant Pharma (VRX) Price Target Lowered to $50 at Citron

October 21, 2015 10:09 AM EDT

Valeant Pharma (NYSE: VRX) Price Target Lowered to $50 at Citron

... More